Compounds > mitomycin
Page last updated: 2024-11-06

mitomycin and Syndrome, VKH (Vogt Koyanagi Harada)

mitomycin has been researched along with Syndrome, VKH (Vogt Koyanagi Harada) in 2 studies

Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.

Research Excerpts

ExcerptRelevanceReference
"To evaluate the outcomes of trabeculectomy with mitomycin-C (MMC) in uveitis associated with Vogt-Koyanagi-Harada disease (VKH)."7.83Outcomes of Trabeculectomy With Mitomycin-C in Uveitis Associated With Vogt-Koyanagi-Harada Disease. ( Alharbi, AH; Aljadaan, I; Almobarak, FA; Morales, J, 2016)
"To evaluate the outcomes of trabeculectomy with mitomycin-C (MMC) in uveitis associated with Vogt-Koyanagi-Harada disease (VKH)."3.83Outcomes of Trabeculectomy With Mitomycin-C in Uveitis Associated With Vogt-Koyanagi-Harada Disease. ( Alharbi, AH; Aljadaan, I; Almobarak, FA; Morales, J, 2016)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Almobarak, FA2
Alharbi, AH2
Aljadaan, I2
Aldhibi, H1
Morales, J1

Other Studies

2 other studies available for mitomycin and Syndrome, VKH (Vogt Koyanagi Harada)

ArticleYear
Phacoemulsification after trabeculectomy in uveitis associated with Vogt-Koyanagi-Harada disease: intermediate-term visual outcome, IOP control and trabeculectomy survival.
    BMC ophthalmology, 2022, May-09, Volume: 22, Issue:1

    Topics: Cataract; Humans; Intraocular Pressure; Mitomycin; Phacoemulsification; Retrospective Studies; Trabe

2022
Outcomes of Trabeculectomy With Mitomycin-C in Uveitis Associated With Vogt-Koyanagi-Harada Disease.
    Journal of glaucoma, 2016, Volume: 25, Issue:6

    Topics: Adult; Alkylating Agents; Cohort Studies; Combined Modality Therapy; Conjunctiva; Female; Glaucoma;

2016